November 20, 2026
Source: drugdu
37

On November 19, Grand Pharma announced that China’s National Medical Products Administration had cleared its in-house nebulized candidate GPN01564 for a Phase I clinical study in respiratory syncytial virus (RSV). The company reported favorable drug development characteristics, safety and efficacy in preclinical studies.
Source: http://finance.eastmoney.com/a/202611193935308279.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.